4.5 Article

Impact of Sodium Glucose Cotransporter 2 Inhibitors on Nonalcoholic Fatty Liver Disease Complicated by Diabetes Mellitus

Journal

HEPATOLOGY COMMUNICATIONS
Volume 5, Issue 5, Pages 736-748

Publisher

JOHN WILEY & SONS LTD
DOI: 10.1002/hep4.1611

Keywords

-

Funding

  1. National Natural Science Foundation of China [31671945]
  2. China Scholarship Council [201706350184, 201706180048]

Ask authors/readers for more resources

SGLT2 inhibitors can protect individuals with NAFLD from severe complications by inhibiting renal glucose reabsorption and other processes that contribute to liver dysfunction.
Sodium glucose cotransporter 2 (SGLT2), a type of membrane protein highly expressed in the kidney, can regulate plasma glucose through the glomerular filtration process by reabsorption from the kidney. SGLT2 inhibitors, which are newly developed oral antidiabetic drugs, can play a role in liver diseases by inhibiting SGLT2-mediated renal glucose reabsorption and inducing glycosuria. Nonalcoholic fatty liver disease (NAFLD) is the most common type of liver disease, resulting in severe liver dysfunction. During the progression of NAFLD, there are some hallmark complications, including lipid metabolism disorders, inflammation induction, and hepatocyte death. Herein, we review several SGLT2 inhibitors that are capable of protecting individuals with NAFLD from severe complications by inhibiting de novo lipogenesis, oxidative responses, inflammation induction, and hepatocyte death.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available